AstraZeneca PLC (AZN)
| Market Cap | 293.77B +39.3% |
| Revenue (ttm) | 60.44B +9.9% |
| Net Income | 10.39B +33.7% |
| EPS | 6.64 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 28.28 |
| Forward PE | 17.82 |
| Dividend | $3.20 (1.71%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 2,797,397 |
| Open | 188.47 |
| Previous Close | 185.20 |
| Day's Range | 186.87 - 190.00 |
| 52-Week Range | 131.03 - 212.71 |
| Beta | 0.28 |
| Analysts | Strong Buy |
| Price Target | n/a |
| Earnings Date | Apr 29, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsNews
FDA panel votes against backing AstraZeneca's breast cancer drug
A panel of outside experts to the U.S. Food and Drug Administration voted against backing the risk-benefit profile of AstraZeneca's breast cancer drug, the company said on Thursday.
AstraZeneca PLC (AZN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
AstraZeneca PLC (AZN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements
Q1 2026 AstraZeneca PLC Earnings Call Transcript
Q1 2026 AstraZeneca PLC Earnings Call Transcript
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca
Option exercise triggers $25M payment to Pinetree. CAMBRIDGE, Mass.
Big pharma can boost Britain: Labour must not let our flagship firms drift away, says RUTH SUNDERLAND
One area where the UK still performs well on an international stage is pharmaceuticals, led by AstraZeneca and GSK.
AstraZeneca (AZN) Announces £300 Million Investment in UK Following Strong Q1 Performance
AstraZeneca (AZN) Announces £300 Million Investment in UK Following Strong Q1 Performance
AstraZeneca (AZN) and GSK Report Strong Q1 Earnings Amid Pricing Policy Concerns
AstraZeneca (AZN) and GSK Report Strong Q1 Earnings Amid Pricing Policy Concerns
AstraZeneca Flexes Cancer Drugs Performance, Pipeline Strength
AstraZeneca Plc (NASDAQ: AZN) on Wednesday reported first-quarter 2026 results that topped Wall Street estimates, driven by strong oncology and rare disease performance. The company posted revenue of...
AstraZeneca Earnings Call Transcript: Q1 2026
Q1 2026 saw 8% revenue growth and 12% operating profit growth, led by strong oncology and rare disease performance, while BioPharmaceuticals faced headwinds from loss of exclusivity. Four positive phase III readouts and 14 new approvals support a robust outlook through 2030.
AstraZeneca makes surprise U-turn with £300m pharma investment
Drugmaker had stalled large-scale UK projects but has now pledged investment at two sites, announced by Keir Starmer Britain’s biggest drugmaker AstraZeneca has said it will invest £300m in the UK in ...
AstraZeneca (AZN) and GlaxoSmithKline (GSK) Exceed Q1 Earnings Expectations
AstraZeneca (AZN) and GlaxoSmithKline (GSK) Exceed Q1 Earnings Expectations
AstraZeneca (AZN) Forecasts Moderate Revenue Growth Through FY26
AstraZeneca (AZN) Forecasts Moderate Revenue Growth Through FY26
AstraZeneca (AZN) Reports Strong Q1 Revenue Growth
AstraZeneca (AZN) Reports Strong Q1 Revenue Growth
AstraZeneca to make $405 million investment in Britain, PM Starmer says
Prime Minister Keir Starmer said on Wednesday that Britain's biggest company AstraZeneca would invest 300 million pounds ($405 million) in the country, after pausing large-scale projects last y...
Shot in the arm for GSK and AstraZeneca from cancer drug sales
The blue chip drug makers saw first quarter earnings beat market expectations.
Cancer drug demand helps AstraZeneca and GSK boost their bottom lines
Pharmaceutical drug giants AstraZeneca and GSK both saw cancer drug sales rise in their latest quarter.
UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies
AstraZeneca and GSK, the U.K.'s second and ninth most valuable companies, both saw first-quarter profits beat expectations early Wednesday.
AstraZeneca (AZN) Reports Strong Q1 Earnings, Beats Expectations
AstraZeneca (AZN) Reports Strong Q1 Earnings, Beats Expectations
AstraZeneca Gets Revenue Boost From Cancer Drugs
AstraZeneca reported rises in revenue and core earnings for the first quarter, saying growing sales of its cancer and rare-disease drugs lifted results.
AstraZeneca beats profit expectations, keeps annual outlook unchanged
AstraZeneca beat first-quarter sales and profit expectations and maintained its 2026 outlook on Wednesday, as demand for its cancer drugs and investments in the U.S. and China helped the dr...
Guardant Health (GH) Faces Minimal Impact from AstraZeneca Advisory Meeting
Guardant Health (GH) Faces Minimal Impact from AstraZeneca Advisory Meeting
Amgen (AMGN) and AstraZeneca (AZN) Launch Real-Time Clinical Trials with FDA
Amgen (AMGN) and AstraZeneca (AZN) Launch Real-Time Clinical Trials with FDA
Pre-Market Earnings Report for April 29, 2026 : ABBV, AZN, TTE, APH, UBS, GD, ADP, REGN, CNI, PSX, ETR, GRMN
The following companies are expected to report earnings prior to market open on 04/29/2026. Visit our Earnings Calendar for a full list of expected earnings releases.AbbVie Inc. (ABBV)is reporting for...
AstraZeneca (AZN) to Test AI-Driven Data Reporting in Clinical Trials
AstraZeneca (AZN) to Test AI-Driven Data Reporting in Clinical Trials